Navigation Links
Regional Biotech Association Warns Legislation Would Make VT Least Friendly State in Nation for Biotechnology and Life Sciences

-Testimony To Legislature Calls For Rejection Of Legislation That Will Cost Vermonters Current And Future Jobs-

MONTPELIER, Vt., April 24 /PRNewswire/ -- In testimony to the Legislature and a full page ad in today's Rutland Herald, the region's largest biotechnology association warned that a bill under consideration by the Vermont Legislature will create the most restrictive and onerous regulatory environment for biotechnology growth and development not only in New England, but in the entire nation. S. 48/H. 270 is the subject of a hearing in Montpelier today.

"Plain and simple, this legislation will harm Vermont's biotechnology and life sciences sector and drive jobs away," said Paula Newton, Chair of the New England Biotech Association (NEBA).

NEBA serves as the regional policy and public affairs voice for the biotechnology and biopharmaceutical community, representing state biotech associations, companies, academic institutions, and other organizations consisting of more than 800 entities.

"Vermont already has one of the strictest pharmaceutical marketing disclosure laws in the country, so the onerous regulatory regime contemplated by the Legislation is wholly unnecessary and should be defeated," continued Newton. "Physicians are trusted professionals, and introducing unreasonably broad controls and prohibitions on the interactions between the biopharmaceutical industry and doctors is unwarranted and contrary to health interests of Vermonters who stand to benefit from miracle drugs." She said the legislation would also eliminate existing protections of trade secrets, create an unneeded new state bureaucracy, and drive away research funding by mandating additional disclosure of expenditures.

Four other states, including New England states Maine and Rhode Island, have recently rejected marketing restriction legislation far less extreme than the Vermont bill, declaring the measures as bad policy with negative consequences for the life sciences industry and the jobs it produces. An overly restrictive disclosure law recently passed in Massachusetts --- less strict than the Vermont proposal -- has resulted in a drop in clinical trials and the cancellation of a major medical convention and the associated tourism and tax revenue.

NEBA is a non-profit, member-driven organization comprised of state biotech associations, companies, academic institutions, and other organizations with a collective mission to support and grow the biotechnology industry in New England.

To find out more about NEBA and view a copy of the Rutland Herald ad, visit

SOURCE New England Biotech Association
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Defeat Autism Now!(R) Regional Conference to be Held in Oklahoma June 13-14, 2009
2. Midwest Research Institute Expands in Kansas to Support Regional Economic Development in Animal Health, Biosecurity, and Bioenergy Sectors
3. Regional Biotech Association Warns Vermont Legislation Could Have Profound Negative Impact
4. Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission
5. New Regional Biotech Association Formed
6. China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products
7. Strengthens Local Market Candidate Reach Through Acquisition
8. Strengthens Local Market Candidate Reach Through Acquisition
9. Strengthens Local Market Candidate Reach Through Acquisition
10. onTargetjobs Announces Acquisition of
11. A Magnetic Gift: Sumter Regional Hospital Receives New MRI as Charitable Donation From Siemens
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
Breaking Biology Technology:
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
Breaking Biology News(10 mins):